Author name: mary

HistoIndex’s AI-based Digital Pathology Platform: A Validated Quantification Tool Recommended in the Guidelines for the Prevention and Treatment of Chronic Hepatitis B in China   SINGAPORE, May 24, 2020 – Singapore medtech company HistoIndex’s AI-based stain-free digital pathology platform has long been established as a suitable tool for global clinical guidelines that outline the assessment, prevention …

HistoIndex’s AI-based Digital Pathology Platform: A Validated Quantification Tool Recommended in the Guidelines for the Prevention and Treatment of Chronic Hepatitis B in China Read More »

qFIBS Demonstrates Suitability for Nonalcoholic Steatohepatitis (NASH) Assessment in Clinical Trials and Patient Care with Full Quantification of All Crucial Histopathological Features   SINGAPORE, Nov. 9, 2019 – qFIBS, a novel automated algorithm developed by HistoIndex, has been shown to accurately distinguish different grades and stages of histological NASH features with a continuous measurement approach. This …

qFIBS Demonstrates Suitability for Nonalcoholic Steatohepatitis (NASH) Assessment in Clinical Trials and Patient Care with Full Quantification of All Histopathological Features Read More »

HistoIndex Announces Global Partnerships To Expand AI-Based Digital Pathology Platform As A Drug Discovery Tool In Preclinical Studies For Nonalcoholic Steatohepatitis (NASH)   The Singapore-based company has fostered partnerships with pharmaceutical and biotech companies, Contract Research Organizations (CROs), academia and government-linked research institutes in empowering NASH drug discovery. SINGAPORE, Oct. 26, 2019 – HistoIndex announces the …

HistoIndex Announces Global Partnerships to Expand AI-Based Digital Pathology Platform as a Drug Discovery Tool in Preclinical Studies for Nonalcoholic Steatohepatitis (NASH) Read More »

LITMUS – Progress towards diagnosing and better treating liver disease   A pioneering European research project, designed to develop new diagnostic tests to assess patients with Non-Alcoholic Fatty Liver Disease (NAFLD) has expanded giving access to more patients. Incorporating several new partners also enables access to even more state-of-the-art technologies.   Liver Investigation: Testing Marker …

LITMUS – Progress towards diagnosing and better treating liver disease Read More »

HistoIndex and ILBS Launch Centre of Excellence in New Delhi for Advanced Diagnostics and Clinical Research on Nonalcoholic Steatohepatitis (NASH)   [Picture by Enterprise Singapore. From Left] Professor Balram Bhargava, Director General, Indian Council of Medical Research; Secretary, Department of Health Research, India, Mr Lim Thuan Kuan, High Commissioner of the Republic of Singapore in …

HistoIndex and ILBS Launch Centre of Excellence in New Delhi for Advanced Diagnostics and Clinical Research on Nonalcoholic Steatohepatitis (NASH) Read More »

HistoIndex’s Second Harmonic Generation (SHG) Technology: A Potentially Important Tool Used In Madrigal’s Phase 2 Nonalcoholic Steatohepatitis (NASH) Clinical Trial   SINGAPORE, Dec. 23, 2018 – HistoIndex’s AI-based SHG technology has the potential to yield important results from NASH clinical trials.  HistoIndex’s SHG technology was featured in Madrigal Pharmaceuticals’ Presidential Plenary presentation during AASLD’s The Liver Meeting® 2018, for its presentation …

HistoIndex’s Second Harmonic Generation (SHG) Technology: A Potentially Important Tool Used In Madrigal’s Phase 2 Nonalcoholic Steatohepatitis (NASH) Clinical Trial Read More »